ArticleBMJ open2026
Diabetes status, fasting glucose and HbA1c, and outcomes after myocardial infarction: a retrospective registry-based Swedish cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to assess cardiovascular (CV) risk across the full spectrum of dysglycaemia levels following myocardial infarction (MI).
designRetrospective registry-based cohort study.
settingAll patients with MI in Sweden registered in the cardiac rehabilitation registry within the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) between 2006 and 2017.
participantsIn total, 47 558 patients over the age of 18 attending cardiac rehabilitation post-MI, with available information on glycaemic levels. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was major adverse CV events (MACE), a composite of all-cause mortality, MI and ischaemic stroke until the end of follow-up (30 June 2018). Secondary outcomes included all the components of MACE, CV mortality and hospitalisation for heart failure.
resultsPre-diabetes and possible diabetes were present in 20.6%, new-onset diabetes in 3.2% and known diabetes in 21.1%. During a median follow-up of 4.7 years, 9321 patients experienced MACE. A stepwise increase across glycaemic categories was observed, with HRs of 1.07 (95% CI 1.00 to 1.14) for pre-diabetes, 1.22 (95% CI 1.11 to 1.34) for possible diabetes, 1.22 (95% CI 1.08 to 1.37) for new-onset diabetes and 1.73 (95% CI 1.64 to 1.82) for known diabetes, compared with normoglycaemia. A near-linear association between fasting glucose and outcomes was observed across all patients, while glycated haemoglobin appears predictive mainly in those with established diabetes.
conclusionsGlycaemic disturbances early after MI, including hyperglycaemia below the diagnostic threshold for diabetes, are associated with a progressively higher risk of adverse outcomes. Beyond routine screening, these findings support close follow-up of at-risk patients, irrespective of diabetes status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.